RSC Advances

This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard Terms & Conditions and the Ethical quidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

www.rsc.org/advances

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Application of Nanoparticle Mediated N-Aryaltion of Amines for the Synthesis of Pharmaceutical Entities using Vit-E analogues as Amphiphile in Water

Atul Kumar,*** and Ajay Kumar Bishnoi**

⁵*Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX* **DOI: 10.1039/b000000x**

First CuI-nanoparticle catalyzed inter and intramolecular N-arylation of amines using vitamin E analogues (TPGS) as amphipile have been developed in water. Application of this transition metalamphiphile C-N bond formation methodology is further extended for the synthesis substituted ¹⁰**indole, bioactive natural product tryptanthrin and intermediates of pharmaceutical entities such as**

Imatinib, Nilotinib, selective D3 agonist/antagonist ligand, and Oxacarbazpine.

Introduction

In twenty first century the chemical transformations are not only evaluated by yield of synthesis /process, but a complete art of

- ¹⁵synthesis is required for the evaluation of synthesis /process. The formula for evaluation of synthesis becomes YES (Yield, Economics - eco friendliness and Stereochemistry).¹ To address economics and environmental sustainability emphasis is direct towards development of green medium, and recyclable reagents.²
- ²⁰Development of green medium is fascinating area since the ionic liquid has been introduced but later on IL biodegradability and greenness in under question mark.³ Therefore water is consider as the best available choice in nature. Water a solvent of life, as almost all the biochemical reaction under goes in water.⁴
- ²⁵However, poor aqueous solubility of organic compounds or reactivity of many transition-metal/organo catalysts are the main limitation, which can be overcome by the introducing organic microenvironment in aqueous phase.⁵

A smart strategy to solve these issues is micellar catalysis.⁶

- ³⁰Recently developed the transition metal coupling reaction catalyzed in water with TPGS-750-M / PTS .⁷ TPGS-750-M is a biodegradable and water-soluble derivative of natural vitamin E, which is formed by esterification of vitamin E succinate with polyethylene glycol (PEG) 1000.⁸ It is consisting of a tocopherol
- ³⁵(vitamin E) hydrophobic group and a PEG hydrophilic group. Micellar catalysis greenness methodology which allows the E factor approach to zero.⁹ Micelles are mainly simple spherical supramolecules, which are formed by amphiphiles in water and have ability to solubilization of both nonpolar and polar 40 substrates, reagents, and catalysts.¹⁰

^aMedicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India, E-mail: dratulsax@gmail.com,

Fax: +91 522-26234051; Tel +91 522-2612411

⁴⁵† Electronic supplementary information (ESI) available: Experimental details and NMR spectra. See supporting

Previous report:

Figure 1. N-aryaltion of amines reaction using Vit-E Amphiphile in Water and their position on HLB Scale

Lipshutz et al. reported N-aryaltion of amines reaction using PTS 60 as nonionic amphiphile with $[(p-ally)]PdCl]_2$ as catalyst, Takasago's as ligand and base in presence of water.¹¹ Inspired by

this report we wish to report here first CuI-nanoparticle catalyzed inter and intramolecular N-arylation of amines using vitamin E analogues (TPGS) as amphipile in water. To the best of our knowledge this is first report on Cu nano and Vitamin E

- ⁵analogues as amphiphile used for catalyzing C-N bond formation. We utilised this methodology for the synthesis of medicinally important indoles¹², anticancer and antitubercular natural product tryptanthrin.¹³ We further extended the protocol for the synthesis of intermediates of pharmaceutical entities such as clinically used
- 10 anticancer $drugs¹⁴$ Imatinib, Nilotinib, selective D3 agonist/antagonist ligand¹⁵ for the treatment of alzimeres and, drug addiction therapy and anticonvulsant Oxacarbazpine.¹⁶ Our initial efforts were focused on the actual effectiveness of an efficient nano catalyst for the N-arylation of amines reaction in
- ¹⁵nanomicelles in water. For this investigation the reaction of bromobenzene and morpholine, taken as a model reaction, control experiment carried out "on water" (i.e., without amphiphile) led to no product formation after 10 h at room temperature as well as refluxing.

20

Table 1. Optimization of reaction conditions for synthesis of N-Aryl amines

^aReaction conditions: ^aReaction conditions: bromobenzene(1.0 mmol), morpholine (1.5 mmol), CuI-NP (3.5 % mole), NaOH as base (3 equ.), aqueous TPGS (2 wt %) amphiphile solution (5 ml) as solvent for 4.5 hr 30 at rt. ^b Isolated yield. np = nanoparticles, TPGS (DL-α-Tocopherol methoxypolyethylene glycol succinate), PTS (Polyoxyethanyl-αtocopheryl sebacate.

We further carried out the reaction with nano CuI catalyst at ³⁵room temperature in water for 10 h but found very less yield. After that we was explore nonionic amphiphile such as oil/water emulsifier and detergent. However, the use of amphiphile (Brij 30) and nano CuI resulted in the formation of the desired product in 65% yield at room temperature. In search of an efficient ⁴⁰amphiphile, we further screened various amphiphiles in the model N-arylation of amines reaction in water such as Brij 30,

85

Triton X-100 and PTS. Therefore, TPGS was found to be the best amphiphile with Nano CuI for the synthesis of N-arylation of amines in water.

 45 The copper(I) salts such as CuBr, CuCl, Cu₂O, and CuI were found to be inferior to CuI nanoparticles (Table 1, entries 11-15). Among the bases studied, Et_3N , K_2CO_3 , $KOHBu$, K_3PO_4 , provided lower yields than NaOH (Table 1, entries 1–5). Of the copper catalysts investigated, CuI nanoparticles were significantly ⁵⁰superior to other catalyst (Table 1, entries 1). In order to evaluate the catalyst loading, the reaction was carried out using 1.5, 3.5, and 5.0 % mole nano CuI at room temperature in water. It was found that 3.5 % mole NP-CuI is sufficient to give the desired product in excellent yield with an enhanced rate (Table 1, entries ⁵⁵8–10).

A control reaction carried out "on water" (i.e., in the absence of amphiphile) confirmed the importance of micellar catalysis in facilitating N-arylation of amines coupling reaction in aqueous media (Table 2).

⁶⁰**Table 2:** Optimisation of Amphiphiles Concentration

A lower concentration of amphiphile was therefore deemed favorable, although too low a concentration or its complete ⁶⁵absence was detrimental. Consequently, TPGS (2 wt %) was selected for further studies. A wide array of aromatic amines, azoles, secondary amines were under goes N-arylation with aryl halides in excellent yields (Scheme 1).

7 85 %

.
ОМ е 8 85 % (85 %)

MeO

 $6^{(90\%)}$

 $5(88%)$

50

Scheme 5: Synthesis of Tryptanthrin

Application of intramolecular N-aryl amination reaction:

Scheme 6: Synthesis of intermediate of Oxacarbazepine:

⁵⁵**Scheme 7:** One pot synthesis of substituted Indole via Intramolecular amination

the intermediate of high profile anticancer drugs such as Imatinib, ⁵Nilotinib. The process exhibits a broad scope for the synthesis of intermediates of imatinib, nilotinib, selective D3 receptor ligand, bioactive natural product tryptanthrin, substituted indoles, and oxacarbazepine respectively (Schemes 2- 7). After completion of reaction, the catalyst was recovered from the reaction mixture by 10 centrifugation and reused for the next fresh reaction. It is noteworthy that the catalyst could be reused at least five times without any significantly loss of efficiency. Therefore, we suspected that because of large surface area, nanoparticles have very high catalytic properties as compare to other catalyst.

To explore this methodology, we have economically synthesized

Application of intermolecular N-aryl amination:

15

Scheme 2: Synthesis of Intermediate of Imatinib:

Scheme 3: Synthesis of N^1 -Selective Intermediate of Nilotinib

Scheme 4: Synthesis of Intermediate of Selective D3 Receptor ligand

40

Figure 2. (a) SEM images of catalyst before the reaction (b) After the 5th run (c) TEM images before the reaction (d) After the $5th$ run, (e) EDX 15 image of fresh catalyst, and (f) EDX image of catalyst after $5th$ run

Table 3. Recyclability of CuI Nanoparticles

20

.

^aCuI nanoparticles (3.5 mol %), bromobenzene (1.0 mmol), morpholine (1.5 mmol) base (1.5 equ.), aqueous TPGS (2 wt %) amphiphile solution (5 ml) as solvent for 4.5 hr at rt (room temperature). ^bThe recovered catalyst was used under identical reaction conditions to those for the first 25 run.

Conclusions

In summary, We have developed first CuI-nanoparticle catalyzed 30 inter and intramolecular N-arylation of amines using vitamin E analogues (TPGS) as amphiphile in aqueous environment. This methodology is further extended to bioactive natural product

tryptanthrin, intermediates of pharmaceutical entity such as life saving anticancer drugs Imitinib, Nilotinib and anticonvulsant ³⁵drug Oxacarbazepine. The amphiphile used is biodegradable and catalyst have have good recyclability. The nano CuI mediated organic synthesis (NAMO-Synthesis) in aqueous media via micellar catalysis has immense future in application in the area of medicinal chemistry and material science.

Experimental Section

General procedure for preparation of CuI nanoparticles

 450.464 g (4 mmol) of dimethylglyoxime (dmgH) and 0.400 g (2) mmol) of $Cu(OAc)₂H₂O$ were added into 50 ml of absolute ethanol in sequence, which was stirred at 0°C for 30 min to get brown precipitates $Cu(dmg)₂$. Then the collected precipitates dispersed in 50 ml of absolute ethanol again, 0.664 g (4 mmol) KI ⁵⁰was added and stirred vigorously for 2 h. After that, the mixture was transferred into 60 mL Teflon-lined stainless steel autoclave. The autoclave was sealed and heated at 180°C for 6 h, and then the reactor bomb is allowed to cool to room temperature. Black precipitates were obtained, then centrifugalized and washed with ⁵⁵ethanol and deionized water for three times to ensure the removal of the impurities. The final product was then dried in a vacuum oven at room temperature for 12 h.¹⁷

General procedure for the N-Arylation of Amine / Azoles:

⁶⁰The N-arylation of amines was carried out in a round bottomed flask. In a typical experiment, a mixture of chlorobenzene (1 mmol), morpholine (1.5 mmol), CuI NPs (3.5 mol%) and NaOH (3 equ.) were dissolved in aqueous TPGS (2 wt %) amphiphile solution (5 ml) as solvent and stirred for the 4.5 hours at room ⁶⁵temperature. The reaction was monitored to completion using TLC. At the end of reaction, the mixture was then cooled to room temperature and poured into distilled water. The products were extracted using EtOAc and the organic layer was dried over anhydrous sodium sulphate (Na_2SO_4) . The solvent was ⁷⁰evaporated in vacuo, the crude products were purified by column chromatography using EtOAc / hexane solvent system.

General procedure for the 2-BromoIndole derivatives in onepot.

- ⁷⁵The intramolecular amination reaction was carried out in a round bottomed flask. In a typical experiment, a mixture of 2-(2,2 dibromovinyl)aniline (1 mmol), CuI NPs (3.5 mol%) and NaOH (3.0 equ.) were dissolved in aqueous TPGS (2 wt %) amphiphile solution (5 ml) as solvent and stirred for the 15 hours at 90 $^{\circ}$ C
- ⁸⁰temperature. The reaction was monitored to completion using TLC. At the end of reaction, the mixture was then cooled to room temperature and poured into distilled water. The products were extracted using EtOAc and the organic layer was dried over anhydrous sodium sulphate (Na_2SO_4) . The solvent was 85 evaporated in vacuo, the crude products were purified by silica column chromatography using EtOAc / hexane solvent system.

Note and References:

90

75

80

85

90

- 1. (a) S. Kobayashi, *Adv. Synth. Catal.* 2002, **344**, 219 b) S. Kobayashi, K. Manabe, *Acc. Chem. Res.* 2002, **35,** 209 – 217. (b) R. Ciriminna, M. Pagliaro, *Org. Process Res. Dev.* 2013, **17**, 1479-1484. (c) U. M. Lindstrom, *Chem. Rev*. 2002, **102**, 2751; c) 5 C. J. Li, *Chem. Rev.* 2005, **105**, 3095. (d) D. J. C. Constable, A. D. Curzons, V. L. Cunningham, *Green Chem.* 2002, **4**, 521-527.
- 2. (a) M.E. Zakrzewska, E. B. Łukasik, R.B. Łukasik, *Chem. Rev.* 2011, **111**, 397-417. (b) N. Azizi, E. Batebi, S. Bagherpour and H. Ghafuri, *RSC Adv.,* 2012, **2**, 2289-2293. (c) D. G. Blackmond, A.
- 10 Armstrong, V. Coombe, A. Wells, *Angew. Chem. Int. Ed.,* 2007, **46,** 3798-3800; *Angew. Chem. Int. Ed.* 2007, **46**, 3798 – 3800. (d) A. Kumar, A. K. Bishnoi, *RSC Adv.,* 2014, **4**, 31973-31976.
- 3. (a) A. Romero, A. Santos, J. Tojo, and A. Rodri ´ guez, *J. Hazard. Mater.,* 2008, **151**, 268–273; (b) N. V. Plechkova, and K. R. 15 Seddon, *Chem. Soc. Rev.*, 2008, **37**, 123–150. (c) A. Kumar, A. K.
- Bishnoi, *RSC Adv.,* 2014, **4**, 41631-41635.
- 4. (a) P. A. Grieco, Organic Synthesis in Water, *Blacky Academic and Professional: London,* 1998. (b) C. J. Li, T. H. Chan, *Organic Reactions in Aqueous Media, John Wiley & Sons: New York,* 20 1997. (c) B. Cornils, W. A. Herrmann, *Aqueous- Phase*
- *Organometallic Chemistry: Concepts and Applications*; *Wiley-VCH: Weinheim,* 1998. 5. (a) T. Tang, T. Metanawin, A. Hebden, P. McGowan, X. S.
- Wang*, Chem. Commun.,* 2010, **46**, 6663-6665. (b) N. S.Ieong, K. 25 Brebis, L. E. Daniel, R.K. O'Reilly, M. I. Gibson, *Chem. Commun.*, 2011, **47**, 11627-11629. (c) A. Xie, M. Cao, Y. Liu, L. Feng, X. Hu, W.Dong, *Eur. J. Org. Chem.* 2014, 436-441.
	- 6. (a) T. Dwars, E. Paetzold, and G. Oehme, *Angew. Chem*. 2005,
- **117**, 7338 7364; *Angew. Chem. Int. Ed.* 2005, **44**, 7174 7199; 30 (b) B. H. Lipshutz, D. W. Chung, B. Rich, *Org. Lett.* 2008, **10**, 3793–3796. (c) B. H. Lipshutz, and A. R. Abela, *Org. Lett.* 2008, **10**, 5329–5332.
	- 7. (a) B. H. Lipshutz, S. Ghorai, *Aldrichimica Acta* **2008**, *41*, 59–72.; *Aldrichimica Acta* 2012, **45**, 3-16. (b) H. Borowy-Borowski, M.
- 35 Sikorska-Walker, P. R. Walker, U.S. Patent 6,045,826, Apr 4, 2000.; U.S. Patent 6,191,172, Feb 20, 2001.; U.S. Patent 6,632,443, Oct 14, 2003. (c) B. H. Lipshutz, N. A. Isley, J. C. Fennewald, and E. D. Slack, *Angew. Chem., Int. Ed.* 2013, **52**, 10952-10958.
- 40 8. B. H. Lipshutz, S. Ghorai, A. R. Abela, R. Moser, T. Nishikata, C. Duplais, and A. Krasovskiy, *J. Org. Chem.* 2011, **76**, 4379–4391.
- 9. (a) N. Miyaura, and A. Suzuki, *Chem. Rev.* 1995, **95**, 2457. (b) B. H. Lipshutz, N. A. Isley, J. C. Fennewald, and E. D. Slack, *Angew.* 45 *Chem., Int. Ed.* 2013, **52**, 10592.
- 10. (a) T. Dwars, E. Paetzold, G. Oehme, *Angew. Chem*. 2005, **117**, 7338 – 7364; Angew. Chem. Int. Ed. 2005, **44**, 7174 – 7199. (b) N.Giri, S. L. James, *Chem. Commun.,* 2011, **47**, 245-247. (c) S. R. K. Minkler, B. H. Lipshutz, N. Krause, *Angew. Chem. Int. Ed.,* 50 2011, **50**, 7820-7823.
	- 11. B. H. Lipshutz, D. W. Chung, and B. Rich, *Adv. Synth. Catal.* 2009, **351**, 1717 – 1721.
- 12. (a) N. K. Kaushik, N. Kaushik, P. Attri, N. Kumar, C. H. Kim, A. K. Verma, and E. H. Choi, *Molecules*, 2013, **18**, 6620. (b) H. 55 Shirinzadeh, B. Eren, H. G. Orhan, S. Suzen, and S. Ozden, *Molecules,* 2010, **15**, 2187.
	- 13. S. Yang, X. Li, F. Hu, Y. Li, Y. Yang, J. Yan, C. Kuang, and Q.Yang, *J. Med. Chem.* 2013, **56**, 8321-8331.
- 14. (a) F. Stegmeier, M. Warmuth, W. R. Sellers, and M. Dorsch, 60 *Clinical Pharmacology & Therapeutics,* 2010*,* **87***,* 543-552*. (b)* H. Kantarjian, *et al.*; *N Engl J Med.,* 2006*,* **354**, 2542–2551.
	- 15. C. Fischer, and B. Koenig, *Beilstein J. Org. Chem.* 2011, **7**, 59–74 16. M. Mazza, G. D. Marca, M. D. Nicola, G. Martinotti, G. Pozzi, L.
- Janiri, P. Bria, and S. Mazza, *Epilepsy & Behavior,* 2007*,* **10***,* 397- 65 401.
	- 17. (a) X. L. Li, X. Y. Zhu, T. L. Duan, and Y. T. Qian, *Solid State Communications*, 2006, **138**, 526-529. (b) H. J. Xu, Y. F. Liang, X. F. Zhou, and Y. S. Feng, *Org. Biomol. Chem.,* 2012, **10**, 2562– 2568.
- 70